DK3835287T3 - Kationisk lipid - Google Patents
Kationisk lipid Download PDFInfo
- Publication number
- DK3835287T3 DK3835287T3 DK19847498.3T DK19847498T DK3835287T3 DK 3835287 T3 DK3835287 T3 DK 3835287T3 DK 19847498 T DK19847498 T DK 19847498T DK 3835287 T3 DK3835287 T3 DK 3835287T3
- Authority
- DK
- Denmark
- Prior art keywords
- cationic lipid
- lipid
- cationic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018151583 | 2018-08-10 | ||
| PCT/JP2019/031411 WO2020032184A1 (ja) | 2018-08-10 | 2019-08-08 | カチオン性脂質 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3835287T3 true DK3835287T3 (da) | 2025-01-02 |
Family
ID=69414814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19847498.3T DK3835287T3 (da) | 2018-08-10 | 2019-08-08 | Kationisk lipid |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12479791B2 (da) |
| EP (1) | EP3835287B1 (da) |
| JP (1) | JP7350749B2 (da) |
| KR (1) | KR102689017B1 (da) |
| CN (2) | CN112533893B (da) |
| AU (1) | AU2019317095B2 (da) |
| BR (1) | BR112021002384B1 (da) |
| CA (1) | CA3109207A1 (da) |
| CO (1) | CO2021001745A2 (da) |
| DK (1) | DK3835287T3 (da) |
| ES (1) | ES3001457T3 (da) |
| FI (1) | FI3835287T3 (da) |
| IL (1) | IL280620B2 (da) |
| MX (1) | MX2021001654A (da) |
| PL (1) | PL3835287T3 (da) |
| PT (1) | PT3835287T (da) |
| SG (1) | SG11202101356YA (da) |
| TW (1) | TWI837161B (da) |
| WO (1) | WO2020032184A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7436990B2 (ja) | 2018-08-10 | 2024-02-22 | 国立大学法人京都大学 | カチオン性脂質を用いた心筋細胞へのトランスフェクション方法 |
| DK3835287T3 (da) | 2018-08-10 | 2025-01-02 | Takeda Pharmaceuticals Co | Kationisk lipid |
| JP7735624B2 (ja) | 2020-08-31 | 2025-09-09 | 武田薬品工業株式会社 | 推論装置、推論方法、推論プログラム、モデル生成方法、推論サービス提供システム、推論サービス提供方法及び推論サービス提供プログラム |
| MX2023003345A (es) * | 2020-09-23 | 2023-07-24 | Translate Bio Inc | Lípidos catiónicos basados en tes. |
| MX2024005608A (es) | 2021-11-10 | 2024-05-22 | Takeda Pharmaceuticals Co | Lipido cationico. |
| WO2023163171A1 (ja) | 2022-02-28 | 2023-08-31 | 武田薬品工業株式会社 | 推論装置、生成装置、推論プログラム及び生成プログラム |
| EP4543847A2 (en) * | 2022-06-23 | 2025-04-30 | Turn Biotechnologies, Inc. | Lipid structures and compositions comprising same |
| EP4562154A2 (en) | 2022-07-29 | 2025-06-04 | Massachusetts Institute of Technology | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPalpha) GENE |
| EP4630561A1 (en) | 2022-12-09 | 2025-10-15 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
| JP2025539561A (ja) * | 2022-12-12 | 2025-12-05 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 新規な脂質化合物及びそれを含む脂質ナノ粒子組成物 |
| CN118108613B (zh) * | 2022-12-26 | 2025-05-06 | 北京新合睿恩生物医疗科技有限公司 | 一种阳离子脂质化合物及制备方法和应用、mRNA递送系统 |
| WO2024210160A1 (en) | 2023-04-07 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Conjugation complex |
| WO2024236361A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Compositions and methods for delivery of nucleic acids to cells |
| WO2024236504A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Sequences and methods for delivery of dna and rna |
| CN121241046A (zh) * | 2023-05-30 | 2025-12-30 | 解放生物股份有限公司 | 脂质化合物、组合物及其用途 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| DE4418965A1 (de) | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US7223887B2 (en) | 2001-12-18 | 2007-05-29 | The University Of British Columbia | Multivalent cationic lipids and methods of using same in the production of lipid particles |
| AU2003240978A1 (en) | 2002-05-31 | 2003-12-19 | Genteric, Inc. | Multi-functional polyamines for delivery of biologically-active polynucleotides |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| CA2611809C (en) | 2005-06-22 | 2018-06-19 | Geron Corporation | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
| US20080145413A1 (en) | 2006-12-19 | 2008-06-19 | Steffen Panzner | Lipids and lipid assemblies comprising transfection enhancer elements |
| KR100807060B1 (ko) | 2007-08-28 | 2008-02-25 | 고려대학교 산학협력단 | 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체 |
| CA2701274A1 (en) | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| US8765465B2 (en) | 2008-03-26 | 2014-07-01 | Kyoto University | Efficient production and use of highly cardiogenic progenitors and cardiomyocytes from embryonic and induced pluripotent stem cells |
| JP2010158206A (ja) | 2009-01-08 | 2010-07-22 | National Institute Of Advanced Industrial Science & Technology | ヒト心筋前駆細胞の選別方法 |
| KR101198715B1 (ko) | 2010-05-14 | 2012-11-13 | 한국생명공학연구원 | 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| EP2788316B1 (en) * | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| SG11201405157PA (en) | 2012-02-24 | 2014-10-30 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| TW201726600A (zh) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
| WO2014071072A2 (en) | 2012-11-02 | 2014-05-08 | Pungente Michael D | Novel cationic carotenoid-based lipids for cellular nucleic acid uptake |
| US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| US10538740B2 (en) | 2014-03-20 | 2020-01-21 | Kyoto University | Method for sorting cardiomyocytes |
| WO2016021683A1 (ja) * | 2014-08-07 | 2016-02-11 | 武田薬品工業株式会社 | カチオン性脂質 |
| CA2975371C (en) | 2015-01-30 | 2024-02-13 | Nof Corporation | Cationic lipid for nucleic acid delivery |
| JP6719352B2 (ja) * | 2016-09-23 | 2020-07-08 | 株式会社総合車両製作所 | 車両用内装パネルとその製造方法 |
| TW201813632A (zh) | 2016-09-28 | 2018-04-16 | 日商協和醱酵麒麟有限公司 | 含有核酸之脂質奈米粒子 |
| EP3551169A4 (en) | 2016-12-09 | 2020-09-09 | Sangamo Therapeutics, Inc. | TARGET-SPECIFIC NUCLEASES ADMINISTRATION |
| MX2020006843A (es) * | 2017-12-27 | 2020-09-03 | Takeda Pharmaceuticals Co | Nanoparticula de lipido que contiene acido nucleico y uso de la misma. |
| TWI802627B (zh) | 2017-12-28 | 2023-05-21 | 日商武田藥品工業股份有限公司 | 陽離子性脂質 |
| TWI825057B (zh) | 2017-12-28 | 2023-12-11 | 國立大學法人京都大學 | 標的基因改變用組成物 |
| DK3835287T3 (da) | 2018-08-10 | 2025-01-02 | Takeda Pharmaceuticals Co | Kationisk lipid |
| JP7436990B2 (ja) | 2018-08-10 | 2024-02-22 | 国立大学法人京都大学 | カチオン性脂質を用いた心筋細胞へのトランスフェクション方法 |
| CN115850104B (zh) | 2022-04-29 | 2023-07-18 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| CN116969851A (zh) | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
-
2019
- 2019-08-08 DK DK19847498.3T patent/DK3835287T3/da active
- 2019-08-08 FI FIEP19847498.3T patent/FI3835287T3/fi active
- 2019-08-08 CN CN201980051986.6A patent/CN112533893B/zh active Active
- 2019-08-08 BR BR112021002384-4A patent/BR112021002384B1/pt active IP Right Grant
- 2019-08-08 AU AU2019317095A patent/AU2019317095B2/en active Active
- 2019-08-08 JP JP2020535882A patent/JP7350749B2/ja active Active
- 2019-08-08 PT PT198474983T patent/PT3835287T/pt unknown
- 2019-08-08 ES ES19847498T patent/ES3001457T3/es active Active
- 2019-08-08 US US17/267,179 patent/US12479791B2/en active Active
- 2019-08-08 CA CA3109207A patent/CA3109207A1/en active Pending
- 2019-08-08 SG SG11202101356YA patent/SG11202101356YA/en unknown
- 2019-08-08 TW TW108128296A patent/TWI837161B/zh active
- 2019-08-08 IL IL280620A patent/IL280620B2/en unknown
- 2019-08-08 CN CN202311153246.8A patent/CN117304048A/zh active Pending
- 2019-08-08 MX MX2021001654A patent/MX2021001654A/es unknown
- 2019-08-08 WO PCT/JP2019/031411 patent/WO2020032184A1/ja not_active Ceased
- 2019-08-08 EP EP19847498.3A patent/EP3835287B1/en active Active
- 2019-08-08 PL PL19847498.3T patent/PL3835287T3/pl unknown
- 2019-08-08 KR KR1020217002801A patent/KR102689017B1/ko active Active
-
2021
- 2021-02-12 CO CONC2021/0001745A patent/CO2021001745A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI837161B (zh) | 2024-04-01 |
| CA3109207A1 (en) | 2020-02-13 |
| CN112533893A (zh) | 2021-03-19 |
| MX2021001654A (es) | 2021-05-12 |
| PT3835287T (pt) | 2024-12-05 |
| BR112021002384A2 (pt) | 2021-05-11 |
| FI3835287T3 (fi) | 2024-12-03 |
| KR20210042089A (ko) | 2021-04-16 |
| KR102689017B1 (ko) | 2024-07-26 |
| TW202021945A (zh) | 2020-06-16 |
| CN112533893B (zh) | 2023-12-22 |
| US12479791B2 (en) | 2025-11-25 |
| SG11202101356YA (en) | 2021-03-30 |
| JP7350749B2 (ja) | 2023-09-26 |
| IL280620B2 (en) | 2024-06-01 |
| CN117304048A (zh) | 2023-12-29 |
| JPWO2020032184A1 (ja) | 2021-08-26 |
| ES3001457T3 (en) | 2025-03-05 |
| BR112021002384B1 (pt) | 2024-01-23 |
| CO2021001745A2 (es) | 2021-03-08 |
| EP3835287A1 (en) | 2021-06-16 |
| EP3835287A4 (en) | 2022-06-08 |
| AU2019317095B2 (en) | 2024-05-02 |
| US20220098142A1 (en) | 2022-03-31 |
| WO2020032184A1 (ja) | 2020-02-13 |
| EP3835287B1 (en) | 2024-10-02 |
| IL280620A (en) | 2021-03-25 |
| PL3835287T3 (pl) | 2025-01-20 |
| IL280620B1 (en) | 2024-02-01 |
| AU2019317095A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3835287T3 (da) | Kationisk lipid | |
| FIC20253006I1 (fi) | Linvoseltamabi | |
| FIC20260010I1 (fi) | imlunestrantti | |
| DK3733641T3 (da) | Kationiske lipider | |
| EP3890716A4 (en) | COMBINATION THERAPIES | |
| DK4328309T3 (da) | Lipidsammensætning | |
| EP3981435A4 (en) | FAT COMPOSITION | |
| HUE058687T2 (hu) | Azonnali elõkészítés | |
| EP3846674C0 (en) | VAGINAL SPECULUM | |
| IL262574B (en) | Cationic lipid | |
| EP3555124C0 (en) | TCR NYESO | |
| EP3781060A4 (en) | CRYOPROBE | |
| EP4007967A4 (en) | Multiply-accumulate unit | |
| EP3967649A4 (en) | LIPIDNANOPARTICLES | |
| EP3784463A4 (en) | Fluorosulfones | |
| HUE061610T2 (hu) | Készítmény | |
| EP3810860C0 (en) | COUPLER | |
| EP3792200A4 (en) | TANK TANK | |
| EP3745904C0 (de) | Stockgriff | |
| EP3878374A4 (en) | Occlusion device | |
| EP3802984C0 (en) | VACUUM FORMING DEVICE | |
| EP3721129A4 (en) | CRYOSPHERE | |
| EP3846153A4 (en) | MEDIUM | |
| EP3805997A4 (en) | LIPIDNANOTABLET | |
| EP3844177A4 (en) | COMBINATION THERAPIES |